BAJAJ BROKING

Notification close image
No new Notification messages
card image
Monika Alcobev IPO is Open!
Apply for the Monika Alcobev IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

5366

543329

WINDLAS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

WINDLAS BIOTECH LIMITED performance

Today’s low

Today’s high

₹ 910.20 ₹ 942.60
₹ 934.15

52 week low

52 week high

₹ 659.00 ₹ 1198.25
₹ 934.15

Open Price

₹ 942.60

Prev. Close

₹ 934.15

Volume (Shares)

28856.00

Total traded value

₹ 269.55

Upper Circuit

₹ 1120.95

Lower Circuit

₹ 747.35

info

WINDLAS BIOTECH LIMITED Share Price Update

As of the latest trading session, WINDLAS BIOTECH LIMITED share price is currently at ₹ 923.45, which is down by ₹ -10.70 from its previous closing. Today, the stock has fluctuated between ₹ 910.20 and ₹ 942.60. Over the past year, WINDLAS BIOTECH LIMITED has achieved a return of 25.17 %. In the last month alone, the return has been -3.37 %. Read More...

Investment Returns

Over 1 Month -3.37% Over 3 Months -7.67% Over 6 Months -4.04% Over 1 Year 25.17%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

WINDLAS BIOTECH LIMITED fundamentals


  • Market cap (Cr)

    1,952.40

  • P/E Ratio (TTM)

    32.23

  • Beta

    1.25

  • Book Value / share

    241.98

  • Return on equity

    12.69%

  • EPS (TTM)

    29.01

  • Dividend yield

    0.62%

  • Net profit/quarter (Cr)

    16.29

info icon alternate text
  • Market cap (Cr)

    1,921.70

  • P/E Ratio (TTM)

    32.18

  • Beta

    1.21

  • Book Value / share

    241.98

  • Return on equity

    12.69%

  • EPS (TTM)

    29.01

  • Dividend yield

    0.62%

  • Net profit/quarter (Cr)

    16.29

info icon alternate text

WINDLAS BIOTECH LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 202.71
Operating Expense 186.82
Net Profit 16.29
Net Profit Margin (%) 8.03
Earnings Per Share (EPS) 7.77
EBITDA 30.49
Effective Tax Rate (%) 21.79
Particulars DEC 2024 (Values in Cr)
Revenue 195.02
Operating Expense 178.78
Net Profit 15.23
Net Profit Margin (%) 7.80
Earnings Per Share (EPS) 7.29
EBITDA 28.37
Effective Tax Rate (%) 23.73
Particulars SEP 2024 (Values in Cr)
Revenue 187.00
Operating Expense 171.54
Net Profit 15.66
Net Profit Margin (%) 8.37
Earnings Per Share (EPS) 7.49
EBITDA 27.89
Effective Tax Rate (%) 22.81
Particulars JUN 2024 (Values in Cr)
Revenue 175.15
Operating Expense 160.97
Net Profit 13.48
Net Profit Margin (%) 7.69
Earnings Per Share (EPS) 6.47
EBITDA 25.00
Effective Tax Rate (%) 26.37
Particulars MAR 2024 (Values in Cr)
Revenue 171.29
Operating Expense 153.17
Net Profit 16.95
Net Profit Margin (%) 9.89
Earnings Per Share (EPS) 8.15
EBITDA 26.38
Effective Tax Rate (%) 24.86
Particulars MAR 2025 (Values in Cr)
Revenue 759.88
Operating Expense 698.13
Net Profit 60.65
Net Profit Margin (%) 7.98
Earnings Per Share (EPS) 29.03
EBITDA 111.75
Effective Tax Rate (%) 23.61
Particulars MAR 2024 (Values in Cr)
Revenue 630.96
Operating Expense 567.40
Net Profit 58.14
Net Profit Margin (%) 9.21
Earnings Per Share (EPS) 27.95
EBITDA 91.55
Effective Tax Rate (%) 24.51
Particulars MAR 2023 (Values in Cr)
Revenue 513.08
Operating Expense 466.00
Net Profit 42.64
Net Profit Margin (%) 8.31
Earnings Per Share (EPS) 19.71
EBITDA 70.21
Effective Tax Rate (%) 25.25
Particulars MAR 2022 (Values in Cr)
Revenue 465.93
Operating Expense 426.60
Net Profit 38.56
Net Profit Margin (%) 8.27
Earnings Per Share (EPS) 18.81
EBITDA 59.61
Effective Tax Rate (%) 16.24
Particulars MAR 2021 (Values in Cr)
Revenue 427.60
Operating Expense 387.17
Net Profit 5.01
Net Profit Margin (%) 1.17
Earnings Per Share (EPS) 2.75
EBITDA 25.43
Effective Tax Rate (%) 55.18
Particulars MAR 2025 (Values in Cr)
Book Value / Share 241.30
ROE % 12.76
ROCE % 16.87
Total Debt to Total Equity 0.04
EBITDA Margin 14.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 216.34
ROE % 13.66
ROCE % 18.07
Total Debt to Total Equity 0.01
EBITDA Margin 14.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.24
ROE % 10.70
ROCE % 14.23
Total Debt to Total Equity 0.01
EBITDA Margin 13.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 181.14
ROE % 12.83
ROCE % 14.77
Total Debt to Total Equity 0.07
EBITDA Margin 12.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 310.59
ROE % 15.19
ROCE % 18.88
Total Debt to Total Equity 0.15
EBITDA Margin 13.47
Particulars MAR 2025 (Values in Cr)
Book Value / Share 241.31
ROE % 12.69
ROCE % 16.79
Total Debt to Total Equity 0.04
EBITDA Margin 14.71
Particulars MAR 2024 (Values in Cr)
Book Value / Share 216.51
ROE % 13.63
ROCE % 18.03
Total Debt to Total Equity 0.01
EBITDA Margin 14.51
Particulars MAR 2023 (Values in Cr)
Book Value / Share 192.42
ROE % 10.69
ROCE % 14.22
Total Debt to Total Equity 0.01
EBITDA Margin 13.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 181.30
ROE % 12.98
ROCE % 14.91
Total Debt to Total Equity 0.07
EBITDA Margin 12.79
Particulars MAR 2021 (Values in Cr)
Book Value / Share 310.39
ROE % 9.39
ROCE % 18.75
Total Debt to Total Equity 0.14
EBITDA Margin 13.51
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 15.92
Total Assets 760.45
Total Liabilities 760.45
Total Equity 505.77
Share Outstanding 20959311
Price to Book Ratio 4.31
Return on Assets (%) 8.02
Return on Capital (%) 11.45
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 30.94
Total Assets 626.20
Total Liabilities 626.20
Total Equity 449.93
Share Outstanding 20798575
Price to Book Ratio 2.37
Return on Assets (%) 9.29
Return on Capital (%) 12.93
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 25.45
Total Assets 528.97
Total Liabilities 528.97
Total Equity 402.27
Share Outstanding 20926628
Price to Book Ratio 1.17
Return on Assets (%) 8.05
Return on Capital (%) 10.58
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 113.82
Total Assets 491.01
Total Liabilities 491.01
Total Equity 394.77
Share Outstanding 21794375
Price to Book Ratio 1.16
Return on Assets (%) 7.75
Return on Capital (%) 9.5
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 31.11
Total Assets 296.12
Total Liabilities 296.12
Total Equity 199.11
Share Outstanding 6411063
Price to Book Ratio 0.00
Return on Assets (%) 5.34
Return on Capital (%) 6.87
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 15.92
Total Assets 760.44
Total Liabilities 760.44
Total Equity 505.78
Share Outstanding 20959311
Price to Book Ratio 4.31
Return on Assets (%) 7.97
Return on Capital (%) 11.38
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 30.89
Total Assets 626.15
Total Liabilities 626.15
Total Equity 450.29
Share Outstanding 20798575
Price to Book Ratio 2.37
Return on Assets (%) 9.28
Return on Capital (%) 12.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 25.45
Total Assets 529.00
Total Liabilities 529.00
Total Equity 402.66
Share Outstanding 20926628
Price to Book Ratio 1.17
Return on Assets (%) 8.06
Return on Capital (%) 10.58
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 113.80
Total Assets 491.02
Total Liabilities 491.02
Total Equity 395.12
Share Outstanding 21794375
Price to Book Ratio 1.16
Return on Assets (%) 7.85
Return on Capital (%) 9.61
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 30.95
Total Assets 295.99
Total Liabilities 295.99
Total Equity 198.99
Share Outstanding 6411063
Price to Book Ratio 0.00
Return on Assets (%) 1.69
Return on Capital (%) 2.18
Particulars MAR 2025 (Values in Cr)
Net Income 79.75
Cash from Operations 89.07
Cash from Investing -74.06
Cash from Financing 1.01
Net change in Cash -4.86
Free Cash Flow 141.26
Particulars MAR 2024 (Values in Cr)
Net Income 77.09
Cash from Operations 127.60
Cash from Investing -92.06
Cash from Financing -15.29
Net change in Cash 1.60
Free Cash Flow 165.29
Particulars MAR 2023 (Values in Cr)
Net Income 57.03
Cash from Operations 70.68
Cash from Investing -14.11
Cash from Financing -43.73
Net change in Cash 3.11
Free Cash Flow 141.57
Particulars MAR 2022 (Values in Cr)
Net Income 45.56
Cash from Operations 18.01
Cash from Investing -154.57
Cash from Financing 130.08
Net change in Cash -15.36
Free Cash Flow 32.81
Particulars MAR 2021 (Values in Cr)
Net Income 21.74
Cash from Operations 17.98
Cash from Investing -20.19
Cash from Financing 0.77
Net change in Cash -7.96
Free Cash Flow 23.83
Particulars MAR 2025 (Values in Cr)
Net Income 79.39
Cash from Operations 89.09
Cash from Investing -74.06
Cash from Financing 1.01
Net change in Cash -4.81
Free Cash Flow 141.29
Particulars MAR 2024 (Values in Cr)
Net Income 77.02
Cash from Operations 127.53
Cash from Investing -92.06
Cash from Financing -15.28
Net change in Cash 1.55
Free Cash Flow 165.21
Particulars MAR 2023 (Values in Cr)
Net Income 57.05
Cash from Operations 70.69
Cash from Investing -14.11
Cash from Financing -43.73
Net change in Cash 3.13
Free Cash Flow 141.58
Particulars MAR 2022 (Values in Cr)
Net Income 46.03
Cash from Operations 17.87
Cash from Investing -154.30
Cash from Financing 130.08
Net change in Cash -15.22
Free Cash Flow 32.67
Particulars MAR 2021 (Values in Cr)
Net Income 11.18
Cash from Operations 17.98
Cash from Investing -20.19
Cash from Financing 0.77
Net change in Cash -7.96
Free Cash Flow 23.82
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.16 32.00 1.97 277.11 34.11 / 77.70
BLISS GVS PHARMA LTD 153.75 19.24 1.54 1621.22 105.05 / 184.95
CIPLA LTD 1485.05 23.31 3.84 119948.65 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 384.45 14.72 3.11 1131.47 194.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.16 92.72 5.71 277.11 34.11 / 77.70
AMRUTAJAN HEALTH LTD 726.25 41.31 6.42 2099.63 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 9237.05 131.92 29.97 23092.63 6222.35 / 10653.05
BLISS GVS PHARMA LTD 153.75 23.51 1.53 1621.22 105.05 / 184.95

WINDLAS BIOTECH LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
934.15 -0.13 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 919.80
  • 26 Days 911.90
  • 10 Days 913.10
  • 50 Days 921.90
  • 12 Days 911.70
  • 100 Days 931.90
  • 20 Days 910.40
  • 200 Days 906.20
896.43 PIVOT

First Support

881.37

First Resistance

907.87

Second Support

869.93

Second Resistance

922.93

Third Support

854.87

Third Resistance

934.37

RSI

44.84

ADX

7.23

MACD

-5.63

Williams % R

-66.18

Commodity Channel Index (CCI)

-24.33

Date

2025-07-11

Week

19055.00

Same Day

13218.00

Month

20083.00

1 Year

1.26

3 Year

0.93

Over 1 Month

-3.37%

down

Over 1 Year

25.17%

down

Over 3 Months

-7.67%

down

Over 3 Years

59.25%

down

Over 6 Months

-4.04%

down

Over 5 Years

0.00%

down

WINDLAS BIOTECH LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
25.25%
Promoter Holdings
62.33%
FII
1.51%
DII
10.89%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Akw Wbl Family Private Trust (through Its Trustees Ashok Vimla Trusteeship Services Private Limited) 8381340.0 (39.99%) Shareholding of Promoter and Promoter Group
Ashok Kumar Windlass 4400000.0 (20.99%) Shareholding of Promoter and Promoter Group
Icici Prudential Pharma Healthcare And Diaganostics (p.h.d) Fund 1251178.0 (5.97%) Public Shareholding
Vimla Windlass 284000.0 (1.36%) Shareholding of Promoter and Promoter Group
Perpetuity Health To Wealth (h2w) Rising Fund 270000.0 (1.29%) Public Shareholding
Persistence Capital Fund I 229244.0 (1.09%) Public Shareholding
Ajay Kumar Aggarwal 214995.0 (1.03%) Public Shareholding
Pgim India Equity Growth Opportunities Fund-series I 214739.0 (1.02%) Public Shareholding
Prachi Jain Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group
Payal Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group
Manoj Kumar Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group
Hitesh Windlass 3.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

WINDLAS BIOTECH LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jul 2025 5.8 Final 21 Jul 2025 Equity shares
17 Sep 2024 5.5 Final 17 Sep 2024 Equity shares
05 Sep 2023 4.0 Final 05 Sep 2023 Equity shares
09 Sep 2022 3.5 Final 12 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jul 2025 5.8 Final 21 Jul 2025 Equity shares
17 Sep 2024 5.5 Final 17 Sep 2024 Equity shares
05 Sep 2023 4.0 Final 05 Sep 2023 Equity shares
09 Sep 2022 3.5 Final 12 Sep 2022 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

WINDLAS BIOTECH LIMITED Share Price

Windlas Biotech Limited (formerly known as Windlas Biotech Private Limited) was incorporated in 2001. The Company converted
from a Private Limited Company to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'. A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun.

The Company is engaged in manufacturing and trading of pharmaceutical products. TheIR manufacturing facilities are located at Dehradun in Uttarakhand. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports.

The Company commenced operations at Dehradun Plant -IV in 2010. It provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products.

Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible.

In 2020, the Company acquired the erstwhile associate -Windlas Healthcare.

To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.

In August 2021, the Company made an Initial Public Offer of 8,729,023 Equity Shares by raising capital from public aggregating to Rs 401.53 Crore, comprising a Fresh Issue of 3,586,956 Equity Shares aggregating to Rs 165 Crore and an Offer for Sale of 5,142,067 Equity Shares
aggregating to Rs 236.53 Crore.

Parent organization Indian Private
NSE symbol WINDLAS
Founded 2001
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Windlas Biotech Ltd?

Answer Field

Windlas Biotech Ltd share price is for NSE ₹ 923.45 & for BSE ₹ 926.95 as on Jul 18 2025 03:30 PM.

What is the Market Cap of Windlas Biotech Ltd Share?

Answer Field

The market cap of Windlas Biotech Ltd for NSE ₹ 1,935.48 & for BSE ₹ 1,942.82 as on Jul 18 2025 03:30 PM.

What is the 52 Week High and Low of Windlas Biotech Ltd?

Answer Field

The 52 Week High and Low of Windlas Biotech Ltd for NSE is ₹ 1,198.25 and ₹ 659.00 and for BSE is ₹ 1,197.00 and ₹ 656.25.

What is 1 year return for Windlas Biotech Ltd?

Answer Field

The 1 year returns on the stock has been 30.39%.

What is the P/E Ratio of Windlas Biotech Ltd Share?

Answer Field

As on Jul 18 2025 03:30 PM the price-to-earnings (PE) ratio for Windlas Biotech Ltd share is 32.23.

What is the PB ratio of Windlas Biotech Ltd Share?

Answer Field

As on Jul 18 2025 03:30 PM, the price-to-book (PB) ratio for Windlas Biotech Ltd share is 241.98.

How to Buy Windlas Biotech Ltd Share?

Answer Field

You can trade in Windlas Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Windlas Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Windlas Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Windlas Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|